Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps. The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) an...
Saved in:
| Published in | Diabetes care Vol. 37; no. 8; pp. 2310 - 2316 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Diabetes Association
01.08.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0149-5992 1935-5548 1935-5548 |
| DOI | 10.2337/dc14-0147 |
Cover
Loading…
| Abstract | To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.
The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.
Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).
The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. |
|---|---|
| AbstractList | To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps. The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp. Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively). The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.OBJECTIVETo determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.RESEARCH DESIGN AND METHODSThe Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).RESULTSSubjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.CONCLUSIONSThe DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps. The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp. Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively). The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. OBJECTIVE To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps. RESEARCH DESIGN AND METHODS The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp. RESULTS Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively). CONCLUSIONS The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. |
| Author | Ly, Trang T. Benassi, Kari Kovatchev, Boris P. Breton, Marc D. Keith-Hynes, Patrick Buckingham, Bruce A. Mize, Benton Clinton, Paula Chernavvsky, Daniel Wilson, Darrell M. Place, Jéróme De Salvo, Daniel |
| Author_xml | – sequence: 1 givenname: Trang T. surname: Ly fullname: Ly, Trang T. organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, School of Paediatrics and Child Health, The University of Western Australia, Perth, Western Australia, Australia – sequence: 2 givenname: Marc D. surname: Breton fullname: Breton, Marc D. organization: Center for Diabetes Technology, University of Virginia, Charlottesville, VA – sequence: 3 givenname: Patrick surname: Keith-Hynes fullname: Keith-Hynes, Patrick organization: Center for Diabetes Technology, University of Virginia, Charlottesville, VA – sequence: 4 givenname: Daniel surname: De Salvo fullname: De Salvo, Daniel organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA – sequence: 5 givenname: Paula surname: Clinton fullname: Clinton, Paula organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA – sequence: 6 givenname: Kari surname: Benassi fullname: Benassi, Kari organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA – sequence: 7 givenname: Benton surname: Mize fullname: Mize, Benton organization: Center for Diabetes Technology, University of Virginia, Charlottesville, VA – sequence: 8 givenname: Daniel surname: Chernavvsky fullname: Chernavvsky, Daniel organization: Center for Diabetes Technology, University of Virginia, Charlottesville, VA – sequence: 9 givenname: Jéróme surname: Place fullname: Place, Jéróme organization: Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, Montpellier, France – sequence: 10 givenname: Darrell M. surname: Wilson fullname: Wilson, Darrell M. organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA – sequence: 11 givenname: Boris P. surname: Kovatchev fullname: Kovatchev, Boris P. organization: Center for Diabetes Technology, University of Virginia, Charlottesville, VA – sequence: 12 givenname: Bruce A. surname: Buckingham fullname: Buckingham, Bruce A. organization: Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28691509$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24879841$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk9rFDEYh4NU7LZ68AtIQAQFx05m8m8uwrKtVSj00BaPITPzppsyk6xJprB3P7gZdmu1HjwlJM_78Eve9wgdOO8Aodek_FTVtTjpO0KLklDxDC1IU7OCMSoP0CIfNQVrmuoQHcV4V5YlpVK-QIcVlaKRlCzQz8t7CM7erhM-H6bOR8Ar71LwA_5u0xprh5dT8qNO0H_EN84aCz2-0gbSFl9tY4IRW4dXazv0AVzme7zs_QCxA5fiTnK93QAm-NTqFhJErNPjfqXHzUv03Oghwqv9eoxuvpxdr74WF5fn31bLi6KjnKeiLyVt69YAECEkF1xkB2UGegAGknWc95p00Bph6qoC0RDTalNRIpigHOpj9Hnn3UztCP2cMOhBbYIdddgqr636-8bZtbr19yobGlaKLHi_FwT_Y4KY1GjzQ4dBO_BTVISXmWty2v-juUW85hWXGX37BL3zU3D5JzLFSlKzqpqFb_4M_zv1Qy8z8G4P6NjpwQTtOhsfOckbksNl7mTHdcHHGMCoziad7Nx2bQdFSjVPlZqnSs1TlSs-PKl4kP7L_gKQgszh |
| CODEN | DICAD2 |
| CitedBy_id | crossref_primary_10_1177_1932296819872225 crossref_primary_10_1056_NEJMoa2210834 crossref_primary_10_1080_17425247_2017_1360862 crossref_primary_10_1089_dia_2019_0011 crossref_primary_10_3390_nu16142210 crossref_primary_10_1007_s00125_016_4022_4 crossref_primary_10_1080_01621459_2018_1537919 crossref_primary_10_1016_S2213_8587_17_30167_5 crossref_primary_10_1089_dia_2015_0144 crossref_primary_10_1016_S1957_2557_20_30003_1 crossref_primary_10_1007_s11892_016_0759_x crossref_primary_10_2337_dc15_2078 crossref_primary_10_1080_17425247_2017_1360866 crossref_primary_10_1089_dia_2015_0345 crossref_primary_10_2337_dc16_0817 crossref_primary_10_2337_dc16_1794 crossref_primary_10_1089_dia_2014_0342 crossref_primary_10_3390_electronics3040609 crossref_primary_10_4155_tde_15_12 crossref_primary_10_4093_dmj_2021_0177 crossref_primary_10_1016_j_ecl_2017_04_010 crossref_primary_10_1007_s40618_016_0495_8 crossref_primary_10_1089_dia_2017_0126 crossref_primary_10_1111_dom_12852 crossref_primary_10_1155_2022_7902418 crossref_primary_10_1089_dia_2019_0139 crossref_primary_10_1089_dia_2016_0432 crossref_primary_10_1186_s42234_018_0015_6 crossref_primary_10_1111_aor_13704 crossref_primary_10_1089_dia_2014_0305 crossref_primary_10_1016_j_diabres_2023_110678 crossref_primary_10_1111_pedi_12603 crossref_primary_10_1016_S2213_8587_16_00015_2 crossref_primary_10_1007_s10439_016_1679_2 crossref_primary_10_2217_dmt_14_48 crossref_primary_10_2337_dc16_0824 crossref_primary_10_1089_dia_2015_0431 crossref_primary_10_1177_1932296815593292 crossref_primary_10_1021_acs_iecr_6b02718 crossref_primary_10_1016_j_jpeds_2017_02_055 crossref_primary_10_2337_dc14_3073 crossref_primary_10_1186_s13098_022_00962_2 crossref_primary_10_1007_s12652_017_0598_x crossref_primary_10_1177_1932296815616134 crossref_primary_10_1177_19322968251315499 crossref_primary_10_2337_dci18_0003 crossref_primary_10_1213_ANE_0000000000001372 crossref_primary_10_1038_nrendo_2014_228 crossref_primary_10_1089_dia_2019_0471 crossref_primary_10_2337_dc21_0932 crossref_primary_10_1089_dia_2018_0308 crossref_primary_10_2337_dc17_0883 crossref_primary_10_1016_j_pcl_2015_04_005 crossref_primary_10_1080_17425247_2020_1713747 crossref_primary_10_1177_1932296816640289 crossref_primary_10_14341_DM9714 crossref_primary_10_1016_j_beem_2015_03_001 crossref_primary_10_1080_17434440_2022_2150546 crossref_primary_10_1177_19322968231212205 crossref_primary_10_1210_clinem_dgac746 crossref_primary_10_1111_pedi_12174 crossref_primary_10_1111_pedi_12731 crossref_primary_10_1016_S1957_2557_21_00179_6 crossref_primary_10_1111_pedi_12454 crossref_primary_10_1016_j_diabet_2015_05_001 crossref_primary_10_1111_dme_12706 crossref_primary_10_1089_dia_2017_0346 crossref_primary_10_1111_pedi_13183 crossref_primary_10_1186_s12967_018_1558_8 crossref_primary_10_1177_1932296819835183 crossref_primary_10_1056_NEJMoa1509351 crossref_primary_10_1007_s11428_015_0046_5 crossref_primary_10_1111_pedi_12867 crossref_primary_10_1016_j_metabol_2018_10_002 crossref_primary_10_1186_s12916_017_0794_8 crossref_primary_10_2337_dc15_2468 crossref_primary_10_1002_cnm_2833 crossref_primary_10_1016_S2213_8587_14_70226_8 crossref_primary_10_1016_S2213_8587_15_00141_2 crossref_primary_10_1016_j_cmpb_2021_106401 crossref_primary_10_1016_j_jpeds_2015_10_015 crossref_primary_10_1186_s12889_018_5376_y crossref_primary_10_1007_s00592_022_01929_5 crossref_primary_10_1007_s40124_015_0083_y crossref_primary_10_2337_dc15_2344 crossref_primary_10_1111_dom_12880 crossref_primary_10_1177_1932296815617968 crossref_primary_10_2337_dc14_3053 crossref_primary_10_2337_dc15_2815 crossref_primary_10_1089_dia_2016_0424 crossref_primary_10_1101_cshperspect_a034389 crossref_primary_10_1210_er_2018_00174 crossref_primary_10_1109_RBME_2017_2749038 crossref_primary_10_1089_dia_2018_0091 |
| Cites_doi | 10.1177/193229681000400611 10.2337/dc11-1430 10.2337/dc12-0761 10.1016/S0022-3476(04)00227-6 10.2337/dc08-0595 10.2337/db11-1445 10.4158/EP13099.OR 10.1089/dia.2013.0139 10.2337/dc12-1965 10.1177/193229681000400428 10.2337/dc07-1967 10.1016/S0140-6736(09)61998-X 10.2337/dc12-0816 10.2337/dc07-0737 10.1056/NEJMoa1206881 10.1177/193229681300700603 10.1177/193229681000400513 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. Copyright American Diabetes Association Aug 2014 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. 2014 |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. – notice: Copyright American Diabetes Association Aug 2014 – notice: 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. 2014 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 ASE FPQ K6X 5PM |
| DOI | 10.2337/dc14-0147 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic British Nursing Index British Nursing Index (BNI) (1985 to Present) British Nursing Index PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic British Nursing Index |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE British Nursing Index |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1935-5548 |
| EndPage | 2316 |
| ExternalDocumentID | PMC4179507 3389842971 24879841 28691509 10_2337_dc14_0147 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural Feature |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR000093 – fundername: NCATS NIH HHS grantid: UL1 TR001085 |
| GroupedDBID | --- -ET ..I .XZ 08P 0R~ 18M 29F 2WC 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAIKC AAKAS AAMNW AAWTL AAYEP AAYXX ABOCM ABPPZ ACGFO ACGOD ADBBV ADZCM AEGXH AENEX AERZD AFOSN AFRAH AHMBA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EJD EMOBN EX3 F5P GX1 H13 HZ~ IAG IAO IEA IHR INH INR IOF IPO KQ8 L7B M0K M5~ O5R O5S O9- OK1 OVD P2P PCD Q2X RHI SV3 TDI TEORI TR2 TWZ VVN W8F WH7 WOQ WOW YHG YOC ~KM .55 .GJ 3O- 41~ 7RV 7X2 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 AAQOH AAQQT AAYJJ ABUWG AFFNX AFKRA AI. AN0 AQUVI ATCPS AZQEC BCR BCU BEC BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C1A CCPQU DWQXO FYUFA GNUQQ GUQSH HCIFZ HMCUK IQODW ITC J5H K9- M0R M0T M1P M2O M2P M2Q N4W NAPCQ PEA PHGZT PQQKQ PROAC PSQYO S0X SJFOW UKHRP VH1 WHG X7M ZCG ZGI ZXP CGR CUY CVF ECM EIF NPM PHGZM PJZUB PPXIY K9. 7X8 ASE FPQ K6X 5PM |
| ID | FETCH-LOGICAL-c466t-d084b3bfee17786767abe45fedee5e85c66da1cebf7f322e791fbaf24175746e3 |
| ISSN | 0149-5992 1935-5548 |
| IngestDate | Thu Aug 21 13:41:28 EDT 2025 Fri Jul 11 09:03:34 EDT 2025 Thu Jul 10 21:54:01 EDT 2025 Mon Jun 30 16:45:37 EDT 2025 Mon Jul 21 06:01:30 EDT 2025 Wed Apr 02 07:25:11 EDT 2025 Thu Apr 24 23:03:00 EDT 2025 Tue Jul 01 04:11:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Endocrinopathy Human Immunopathology Nutrition Toxicity Autoimmune disease Metabolic diseases Glucose Surveillance Type 1 diabetes Adolescent Safety Therapeutic camp Child Endocrinology |
| Language | English |
| License | CC BY 4.0 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c466t-d084b3bfee17786767abe45fedee5e85c66da1cebf7f322e791fbaf24175746e3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Evidence Based Healthcare-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4179507 |
| PMID | 24879841 |
| PQID | 1550135226 |
| PQPubID | 47715 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4179507 proquest_miscellaneous_1609509466 proquest_miscellaneous_1548636268 proquest_journals_1550135226 pubmed_primary_24879841 pascalfrancis_primary_28691509 crossref_citationtrail_10_2337_dc14_0147 crossref_primary_10_2337_dc14_0147 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-08-01 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States – name: Alexandria |
| PublicationTitle | Diabetes care |
| PublicationTitleAlternate | Diabetes Care |
| PublicationYear | 2014 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | Swan (2022031220061947900_B15) 2009; 32 Kovatchev (2022031220061947900_B3) 2010; 4 Hughes (2022031220061947900_B13) 2010; 4 Desalvo (2022031220061947900_B16) 2014; 16 Hovorka (2022031220061947900_B4) 2011 O'Grady (2022031220061947900_B5) 2012; 35 Kovatchev (2022031220061947900_B6) 2013; 36 Swan (2022031220061947900_B10) 2008; 31 Grosman (2022031220061947900_B8) 2010; 4 Phillip (2022031220061947900_B17) 2013; 368 Weinzimer (2022031220061947900_B2) 2008; 31 Breton (2022031220061947900_B7) 2012; 61 Place (2022031220061947900_B12) 2013; 7 Bergman (2022031220061947900_B14) 1979; 236 Elleri (2022031220061947900_B18) 2013; 36 Cemeroglu (2022031220061947900_B9) 2013; 19 Hovorka (2022031220061947900_B1) 2010; 375 Murphy (2022031220061947900_B19) 2011; 34 Hasan (2022031220061947900_B11) 2004; 144 22875230 - Diabetes Care. 2012 Nov;35(11):2182-7 23757622 - Endocr Pract. 2013 Sep-Oct;19(5):805-11 15212060 - J Pediatr. 2004 Jun;144(6):834 18252903 - Diabetes Care. 2008 May;31(5):934-9 24168317 - Diabetes Technol Ther. 2014 Jan;16(1):1-7 20663463 - J Diabetes Sci Technol. 2010 Jul;4(4):961-75 21129332 - J Diabetes Sci Technol. 2010 Nov;4(6):1374-81 19017777 - Diabetes Care. 2009 Feb;32(2):240-4 20920434 - J Diabetes Sci Technol. 2010 Sep;4(5):1146-55 22011408 - Diabetes Care. 2011 Dec;34(12):2527-9 17909083 - Diabetes Care. 2008 Jan;31(1):44-6 21493665 - BMJ. 2011;342:d1855 20138357 - Lancet. 2010 Feb 27;375(9716):743-51 22688340 - Diabetes. 2012 Sep;61(9):2230-7 23801798 - Diabetes Care. 2013 Jul;36(7):1851-8 23193217 - Diabetes Care. 2013 Apr;36(4):838-44 443421 - Am J Physiol. 1979 Jun;236(6):E667-77 24351169 - J Diabetes Sci Technol. 2013 Nov;7(6):1427-35 23445093 - N Engl J Med. 2013 Feb 28;368(9):824-33 |
| References_xml | – volume: 4 start-page: 1374 year: 2010 ident: 2022031220061947900_B3 article-title: Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results publication-title: J Diabetes Sci Tech doi: 10.1177/193229681000400611 – volume: 34 start-page: 2527 year: 2011 ident: 2022031220061947900_B19 article-title: Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series publication-title: Diabetes Care doi: 10.2337/dc11-1430 – volume: 35 start-page: 2182 year: 2012 ident: 2022031220061947900_B5 article-title: The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes publication-title: Diabetes Care doi: 10.2337/dc12-0761 – volume: 144 start-page: 834 year: 2004 ident: 2022031220061947900_B11 article-title: Mini-dose glucagon is effective at diabetes camp publication-title: J Pediatr doi: 10.1016/S0022-3476(04)00227-6 – volume: 32 start-page: 240 year: 2009 ident: 2022031220061947900_B15 article-title: Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy publication-title: Diabetes Care doi: 10.2337/dc08-0595 – volume: 61 start-page: 2230 year: 2012 ident: 2022031220061947900_B7 article-title: Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia publication-title: Diabetes doi: 10.2337/db11-1445 – volume: 19 start-page: 805 year: 2013 ident: 2022031220061947900_B9 article-title: Basal and bolus insulin requirements in children, adolescents and young adults with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII): effect of age and puberty publication-title: Endocr Pract doi: 10.4158/EP13099.OR – volume: 16 start-page: 1 year: 2014 ident: 2022031220061947900_B16 article-title: Remote glucose monitoring in camp setting reduces the risk of prolonged nocturnal hypoglycemia publication-title: Diabetes Technol Ther doi: 10.1089/dia.2013.0139 – volume: 36 start-page: 1851 year: 2013 ident: 2022031220061947900_B6 article-title: Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas publication-title: Diabetes Care doi: 10.2337/dc12-1965 – volume: 4 start-page: 961 year: 2010 ident: 2022031220061947900_B8 article-title: Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events publication-title: J Diabetes Sci Tech doi: 10.1177/193229681000400428 – volume: 31 start-page: 934 year: 2008 ident: 2022031220061947900_B2 article-title: Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas publication-title: Diabetes Care doi: 10.2337/dc07-1967 – volume: 236 start-page: E667 year: 1979 ident: 2022031220061947900_B14 article-title: Quantitative estimation of insulin sensitivity publication-title: Am J Physiol – volume: 375 start-page: 743 year: 2010 ident: 2022031220061947900_B1 article-title: Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61998-X – volume: 36 start-page: 838 year: 2013 ident: 2022031220061947900_B18 article-title: Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial publication-title: Diabetes Care doi: 10.2337/dc12-0816 – volume: 31 start-page: 44 year: 2008 ident: 2022031220061947900_B10 article-title: Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes publication-title: Diabetes Care doi: 10.2337/dc07-0737 – volume: 368 start-page: 824 year: 2013 ident: 2022031220061947900_B17 article-title: Nocturnal glucose control with an artificial pancreas at a diabetes camp publication-title: N Engl J Med doi: 10.1056/NEJMoa1206881 – volume: 7 start-page: 1427 year: 2013 ident: 2022031220061947900_B12 article-title: DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials publication-title: J Diabetes Sci Tech doi: 10.1177/193229681300700603 – volume: 4 start-page: 1146 year: 2010 ident: 2022031220061947900_B13 article-title: Hypoglycemia prevention via pump attenuation and red-yellow-green “traffic” lights using continuous glucose monitoring and insulin pump data publication-title: J Diabetes Sci Tech doi: 10.1177/193229681000400513 – start-page: d1855 volume-title: BMJ year: 2011 ident: 2022031220061947900_B4 article-title: Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies – reference: 19017777 - Diabetes Care. 2009 Feb;32(2):240-4 – reference: 20663463 - J Diabetes Sci Technol. 2010 Jul;4(4):961-75 – reference: 22688340 - Diabetes. 2012 Sep;61(9):2230-7 – reference: 23801798 - Diabetes Care. 2013 Jul;36(7):1851-8 – reference: 22875230 - Diabetes Care. 2012 Nov;35(11):2182-7 – reference: 443421 - Am J Physiol. 1979 Jun;236(6):E667-77 – reference: 24351169 - J Diabetes Sci Technol. 2013 Nov;7(6):1427-35 – reference: 17909083 - Diabetes Care. 2008 Jan;31(1):44-6 – reference: 18252903 - Diabetes Care. 2008 May;31(5):934-9 – reference: 20138357 - Lancet. 2010 Feb 27;375(9716):743-51 – reference: 15212060 - J Pediatr. 2004 Jun;144(6):834 – reference: 23757622 - Endocr Pract. 2013 Sep-Oct;19(5):805-11 – reference: 21129332 - J Diabetes Sci Technol. 2010 Nov;4(6):1374-81 – reference: 23445093 - N Engl J Med. 2013 Feb 28;368(9):824-33 – reference: 22011408 - Diabetes Care. 2011 Dec;34(12):2527-9 – reference: 24168317 - Diabetes Technol Ther. 2014 Jan;16(1):1-7 – reference: 21493665 - BMJ. 2011;342:d1855 – reference: 23193217 - Diabetes Care. 2013 Apr;36(4):838-44 – reference: 20920434 - J Diabetes Sci Technol. 2010 Sep;4(5):1146-55 |
| SSID | ssj0004488 |
| Score | 2.4715867 |
| Snippet | To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents... OBJECTIVE To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 2310 |
| SubjectTerms | Adolescent Adult Algorithms Automation Biological and medical sciences Biosensing Techniques - instrumentation Blood Glucose - drug effects Blood Glucose - metabolism Blood Glucose Self-Monitoring - instrumentation Camping Child Children & youth Circadian Rhythm Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - epidemiology Diabetes. Impaired glucose tolerance Emerging Technologies and Therapeutics Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female General aspects Glucose Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Insulin - administration & dosage Insulin - adverse effects Insulin Infusion Systems - adverse effects Intention to Treat Analysis Male Median Medical sciences Metabolic diseases Protocol Teenagers Young Adult |
| Title | Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24879841 https://www.proquest.com/docview/1550135226 https://www.proquest.com/docview/1548636268 https://www.proquest.com/docview/1609509466 https://pubmed.ncbi.nlm.nih.gov/PMC4179507 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9NAEF_KCSKI-G30PFbxQYipzddm81hatSpVwR7eW0g2u3pwpsVLBX323_N_cia72SSliN5LSJNNdpv5ZXZmM_MbQp4oKQWLY-EpDPaLYErxUpj3PBFIVcA5GTbFYJbv2OI4enMSn4xGv3tRS9u6GIufe_NKLiJVOAZyxSzZ_5CsvSkcgH2QL2xBwrD9Jxm_xzq56F27r0zk-cxEnn_SKWvudFuvwSbVK5pgXyq0OD_mCgM1NVl5k_bXZnTjKvq043jSt0FX1fXdebtKm9fdPn666Nu39gRGlNlgn0aQOCt-dlfjbgFAtqH7yBcwH3e6H3r1Fj8GRQRsQtFcwvjPvq-7_Pj-woUf2bC5upcrAE_CjmwXkO2KZ-rFqS6YN5ZaS6dh7IEdxPtqXHPHGLjyvk4OTeCsbH-yfXNHEDbsA6XAkfqaBrSHoc3XBkQBOHgp11xdO0TdH5YzLOcWI7fBpQC8Fpwn5q_fdmm6UVMG1f4jTXSF_T63vSI5teliYCld3eTn8NIqXW1lnzu0G9XbM5NW18k149_QqQbrDTKS1U1yeWkiOG6RXxaz1GCWGsxSBBvNK2ox-4waxFKNWKoRS08r2iIW2pe0h1h9E0Qs9WkrcprX3T4i9jY5fvliNVt4phKIJyLGaq-c8KgIC1AsPvIdJiyBa6JYyVLKWPJYMFbmvpCFShQoF5mkvipyBdZpEicRk-EdclCtK3mP0DzNC15OlM9LGbFUccFCBUZsCccmQiqHPG2feiYMTT5WaznLwF1GWWUoqwxl5ZDHtulGc8Psa3Q0EJ1tGXCWgjeWOuSwlWVmdMt5hgsHfuMbOeSRPQ2aHz_n5ZVcb7FNxBmySfG_tEE-yQnWkHDIXQ2PbgAGZw5JBsCxDZB5fnimOv3SMNAbnN-_8JUPyJVOJRySg_rbVj4E674ujpp35g_zmP_p |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overnight+Glucose+Control+With+an+Automated%2C+Unified+Safety+System+in+Children+and+Adolescents+With+Type+1+Diabetes+at+Diabetes+Camp&rft.jtitle=Diabetes+care&rft.au=Ly%2C+Trang+T.&rft.au=Breton%2C+Marc+D.&rft.au=Keith-Hynes%2C+Patrick&rft.au=De+Salvo%2C+Daniel&rft.date=2014-08-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.eissn=1935-5548&rft.volume=37&rft.issue=8&rft.spage=2310&rft.epage=2316&rft_id=info:doi/10.2337%2Fdc14-0147&rft_id=info%3Apmid%2F24879841&rft.externalDocID=PMC4179507 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |